Inhibikase Therapeutics Inc (FRA:IQT0)
€ 3.21 0 (0%) Market Cap: 5.05 Mil Enterprise Value: -14.25 Mil PE Ratio: 0 PB Ratio: 4.08 GF Score: 38/100

Inhibikase Therapeutics Inc at Truist Securities Life Sciences Summit (April Series) Transcript

Apr 13, 2021 / NTS GMT
Release Date Price: €27.12 (-3.00%)
Robyn Karnauskas
Truist Securities, Inc. - Moderator

Good morning, everyone. I hope everyone can hear me. I'm not quite sure if we've lost everyone. Milton, are you on?

Milton Werner
Inhibikase Therapeutics, Inc. - President & CEO

I am.

Robyn Karnauskas
Truist Securities, Inc. - Moderator

Okay. Great. So welcome, everyone to the Truist Life Sciences Summit Conference Call series. This morning, we have Inhibikase. Ticker, IKT. I'm very excited to share with you the story. And we have the CEO, Milton Werner to go through it a little bit.

Before we start, feel free to e-mail me with questions. But I have to read some disclosures. So one second. The call is arranged by Truist Securities Research for the use by institutional investors and issuer clients as defined by FINRA.

If you're not an institutional investor or an issuer, please disconnect at this time. For required disclosures, please see our website at Truist Securities, or our research equity research library.

So I'm excited to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot